AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Immunology

• Publication date

  2009-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.0901474PMID 19864596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inflammatory signals in dendritic cell activation and the induction of adaptive immunity

  2009cited by this paper
• Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities.

  2009cited by this paper
• The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding

  2009cited by this paper
• Mechanism of action of clinically approved adjuvants.

  2009cited by this paper
• Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

  2009cited by this paper
• Towards an understanding of the adjuvant action of aluminium

  2009cited by this paper
• Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

  2008cited by this paper
• Antigen presentation by monocytes and monocyte-derived cells.

  2008cited by this paper
• Molecular and cellular signatures of human vaccine adjuvants

  2008cited by this paper
• T follicular helper (TFH) cells in normal and dysregulated immune responses.

  2008cited by this paper
• Mechanisms and consequences of dendritic cell migration.

  2008cited by this paper
• Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

  2008cited by this paper
• Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

  2008cited by this paper
• Monocyte-mediated defense against microbial pathogens.

  2008cited by this paper
• A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response

  2008cited by this paper
• Vaccine adjuvants alter TCR-based selection thresholds.

  2008cited by this paper
• Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

  2008cited by this paper
• GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

  2007cited by this paper
• Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.

  2007cited by this paper
• Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release1

  2007cited by this paper
• The perfect mix: recent progress in adjuvant research

  2007cited by this paper
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

  2007cited by this paper
• Cutting Edge: T Cells Respond to Lipopolysaccharide Innately via TLR4 Signaling1

  2007cited by this paper
• Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

  2007cited by this paper
• The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4

  2007cited by this paper
• New hepatitis B vaccine formulated with an improved adjuvant system

  2007cited by this paper
• (How) do aluminium adjuvants work?

  2006cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt

  2006cited by this paper
• Toll-like receptors and IFN-alpha: partners in autoimmunity.

  2006cited by this paper
• Toll-like receptors and IFN-α: partners in autoimmunity

  2006cited by this paper
• Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

  2006influential reference
• Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction.

  2006cited by this paper
• Toll‐like receptor stimulation as a third signal required for activation of human naive B cells

  2006cited by this paper
• Toll-like receptors in systemic autoimmune disease

  2006cited by this paper
• Expression and function of Toll-like receptor on T cells.

  2005cited by this paper
• Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta.

  2005cited by this paper
• Control of B-cell responses by Toll-like receptors

  2005cited by this paper
• Activation of dendritic cells by human papillomavirus‐like particles through TLR4 and NF‐κB‐mediated signalling, moderated by TGF‐β

  2005cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial

  2005cited by this paper
• B Lymphocyte Activation by Human Papillomavirus-Like Particles Directly Induces Ig Class Switch Recombination via TLR4-MyD881

  2005cited by this paper
• Papillomavirus virus‐like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells

  2005cited by this paper
• Toll-like receptor control of the adaptive immune responses

  2004influential reference
• Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C(2)C(12) myoblasts via Toll-like receptor-4 and c-Jun NH(2)-terminal kinase pathways.

  2004cited by this paper
• Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

  2004cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A.

  2004cited by this paper
• Chemokines and chemokine receptors: their manifold roles in homeostasis and disease.

  2004cited by this paper
• The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells.

  2003cited by this paper
• Blood monocytes consist of two principal subsets with distinct migratory properties.

  2003cited by this paper
• Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

  2003influential reference
• Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529

  2003cited by this paper
• Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells

  2003cited by this paper
• Immunopotentiators in modern vaccines

  2003cited by this paper
• Monophosphoryl Lipid A Activates Both Human Dendritic Cells and T Cells1

  2002influential reference
• Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells

  2002cited by this paper
• Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis

  2001cited by this paper
• Monophosphoryl lipid A stimulated up‐regulation of reactive oxygen intermediates in human monocytes in vitro

  2001cited by this paper
• Human Dendritic Cells Are Activated by Chimeric Human Papillomavirus Type-16 Virus-Like Particles and Induce Epitope-Specific Human T Cell Responses In Vitro1

  2001cited by this paper
• Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation.

  2001cited by this paper
• Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells1

  2001cited by this paper
• Bacterial Lipopolysaccharide and IFN-γ Induce Toll-Like Receptor 2 and Toll-Like Receptor 4 Expression in Human Endothelial Cells: Role of NF-κB Activation1

  2001cited by this paper
• Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells1

  2000cited by this paper
• Toll-Like Receptor 4, But Not Toll-Like Receptor 2, Is a Signaling Receptor for Escherichia and Salmonella Lipopolysaccharides1

  2000cited by this paper
• Cutting Edge: Repurification of Lipopolysaccharide Eliminates Signaling Through Both Human and Murine Toll-Like Receptor 21

  2000cited by this paper
• The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells.

  2000cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo.

  1999cited by this paper
• Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice.

  1997cited by this paper
• Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.

  1982cited by this paper
• Brief Definitive Report Stimulation of Toll-like Receptor 3 and 4 Induces Interleukin-1 ␤ Maturation by Caspase-8

  year unknowncited by this paper

• Intranasal unadjuvanted LcrV boosts parental Yersinia OMV primed lung immunity against pneumonic plague in mice

  2026cites this paper
• The application of nanomaterials in vaccine adjuvants

  2026cites this paper
• Emerging novel methodologies to understand and strategically target long-lived plasma cells in vaccine design to induce durable immunity.

  2026cites this paper
• Disrupting PDGFRA-driven immune evasion in glioma: vaccine-based strategies on the horizon

  2026cites this paper
• Outer membrane vesicles as a versatile nanoplatform for advanced vaccine development and immunotherapy

  2026cites this paper
• The recent advances in vaccine adjuvants

  2025cites this paper
• AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells

  2025cites this paper
• New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation

  2025cites this paper
• An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics.

  2025cites this paper
• Recombinant Chimeric Virus-like Particles of Human Papillomavirus Produced by Distinct Cell Lineages: Potential as Prophylactic Nanovaccine and Therapeutic Drug Nanocarriers

  2025cites this paper
• Application prospect of polysaccharide in the development of vaccine adjuvants.

  2025cites this paper
• STING-activating layered double hydroxide nano-adjuvants for enhanced cancer immunotherapy.

  2025cites this paper
• Novel nanoemulsion adjuvant stabilized by TPGS possesses equivalent physicochemical properties, Turbiscan stability, and adjuvanticity to AS03 for eliciting robust immunogenicity of subunit vaccines in mice

  2025cites this paper
• De novo design of protein minibinder agonists of TLR3

  2025cites this paper
• Enantiomer-dependent and modification-free DNA matrix as an adjuvant for subunit vaccines against SARS-CoV-2 or pneumococcal infections

  2025cites this paper
• Elicitation of protective immune responses against influenza a viruses in elderly ferrets by adjuvanted recombinant universal influenza hemagglutinin vaccines

  2025cites this paper
• Ageing with HIV-1: immunological challenges for effective vaccination

  2025cites this paper
• A COMPREHENSIVE REVIEW OF VACCINE ADJUVANTS: CURRENT APPLICATIONS, DEVELOPMENT, AND IN SILICO DESIGN

  2025cites this paper
• Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms

  2025cites this paper
• Exploring the immune responses triggered by vaccine formulations containing the recombinant Schistosoma mansoni 14kDa fatty acid-binding protein

  2025cites this paper
• Study on the adjuvant activity and mechanism of action of a novel Monophosphoryl Lipid A.

  2025cites this paper
• Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.

  2025cites this paper
• Advances in vaccine adjuvant development and future perspectives

  2025cites this paper
• Immune responses to human papillomavirus infection and vaccination

  2025cites this paper
• The ongoing challenge of prevention of pertussis in infants: what’s new in 2024?

  2025cites this paper
• Metabolic adaptations driving innate immune memory: mechanisms and therapeutic implications

  2025cites this paper
• Tamibarotene-Loaded Nanoemulsion Incorporating Toll-like Receptor 2/6 Agonist as an Intramuscular Adjuvant System Enhances Gastrointestinal Mucosal Immunity.

  2025cites this paper
• Vaccine formulation design: challenges and opportunities

  2025cites this paper
• Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria.

  2025cites this paper
• Guided design for the development of an evolution-proof influenza vaccine.

  2025cites this paper
• Development of therapeutic cancer vaccines based on cancer immunity cycle

  2025cites this paper
• Construction strategies of whole tumor cell vaccines.

  2025cites this paper
• Human papillomavirus infection and vaccination with thyroid diseases: mechanistic links and immunological insights

  2025cites this paper
• Exploring the Role of Pattern Recognition Receptors as Immunostimulatory Molecules

  2025cites this paper
• Sequentially Regulated Lysosomal Assembly Formation and Degradation for Potent Inflammasome Driven Immunotherapy.

  2025cites this paper
• Brief Comparison of Novel Influenza Vaccine Design Strategies

  2025cites this paper
• Integrating immune adverse outcome pathways into vaccine safety evaluation

  2025cites this paper
• Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy

  2025cites this paper
• Monophosphoryl Lipid A induces tolerance against single prolonged stress-induced PTSD-like behavior and neuroinflammatory responses in mice.

  2025cites this paper
• PV-10 enhances immune responses in hepatitis B vaccination through STING pathway

  2025cites this paper
• Adjuvant activity of a small molecule TLR4 agonist discovered via structure-based virtual screening

  2025cites this paper
• Aluminum-based salts: a novel and simple way to treat molluscum contagiosum and cutaneous warts

  2025cites this paper
• Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies

  2025cites this paper
• Vaccine adjuvants: Insights into development, present and future perspective

  2025cites this paper
• Toll-like Receptor (TLR) Response in Chikungunya Virus Infection: Mechanism of Activation, Immune Evasion, and Use of TLR Agonists in Vaccine Development

  2025cites this paper
• Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

  2025cites this paper
• Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy

  2025cites this paper
• Iterative selection of lipid nanoparticle vaccine adjuvants for rapid elicitation of tumoricidal CD8⁺ T cells

  2025cites this paper
• Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy

  2025cites this paper
• Dynamic Activation of NADPH Oxidases in Immune Responses Modulates Differentiation, Function, and Lifespan of Plasma Cells

  2025cites this paper
• Cancer vaccines: platforms and current progress

  2025cites this paper
• Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine

  2025cites this paper
• Application of in-silico approaches in subunit vaccines: Overcoming the challenges of antigen and adjuvant development.

  2025cites this paper
• Age-related changes in the immune system and challenges for the development of age-specific vaccines

  2025cites this paper
• Current Status and Potential of Immune Adjuvants in Mycotoxin Immune Enhancement: Mechanisms, Innovations, and Applications.

  2025cites this paper
• A novel MF59 and CpG1018 adjuvant combination enhances the humoral and cellular immune responses against a truncated varicella-zoster viral glycoprotein E.

  2025cites this paper
• Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum.

  2025cites this paper
• Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity

  2025cites this paper
• Vaccine adjuvants: Tailoring innate recognition to send the right message.

  2024cites this paper
• De novo design of protein minibinder agonists of TLR3

  2024cites this paper
• Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response

  2024cites this paper
• Silicon or Calcium Doping Coordinates the Immunostimulatory Effects of Aluminum Oxyhydroxide Nanoadjuvants in Prophylactic Vaccines.

  2024cites this paper
• Adjuvants in cutaneous vaccination: A comprehensive analysis.

  2024cites this paper
• Vaccine adjuvants for infectious disease in the clinic

  2024cites this paper
• Novel HER2-based multi-epitope vaccine (HER2-MEV) against HER2-positive breast cancer: In silico design and validation.

  2024cites this paper
• A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice

  2024cites this paper
• Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine.

  2024cites this paper
• Vaccine adjuvants: current status, research and development, licensing, and future opportunities.

  2024cites this paper
• Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

  2024cites this paper
• Progress and prospect of polysaccharides as adjuvants in vaccine development

  2024cites this paper
• Unleashing the role of potential adjuvants in leishmaniasis.

  2024cites this paper
• Glioblastoma vaccines: past, present, and opportunities

  2024cites this paper
• Gaston Ramon’s Big Four

  2024cites this paper
• The scientific journey of a novel adjuvant (AS37) from bench to bedside

  2024cites this paper
• Adjuvant potential of Peyssonnelia caulifera extract on the efficacy of an influenza vaccine in a murine model

  2024cites this paper
• Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria

  2024cites this paper
• An immunoinformatics approach for a potential NY-ESO-1 and WT1 based multi-epitope vaccine designing against triple-negative breast cancer

  2024cites this paper
• Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions

  2024cites this paper
• Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response

  2024cites this paper
• Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?—An updated systematic review and meta‐analysis based on timing of vaccination

  2024cites this paper
• An Overview of the Types of Adjuvants Used in the Vaccination Industry And Their Mechanisms of Action

  2024cites this paper
• Structural Assessment of Chlamydia trachomatis Major Outer Membrane Protein (MOMP)-Derived Vaccine Antigens and Immunological Profiling in Mice with Different Genetic Backgrounds

  2024cites this paper
• A Case of Progressive Lipoatrophy due to Lupus Erythematosus Panniculitis Induced by Quadrivalent Human Papillomavirus Vaccine

  2024cites this paper
• Relationship between Endotoxin Content in Vaccine Preclinical Formulations and Animal Welfare: An Extensive Study on Historical Data to Set an Informed Threshold

  2024cites this paper
• Current status and future directions for the development of human papillomavirus vaccines

  2024cites this paper
• Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors

  2024influential citation
• Adjuvant system AS01: from mode of action to effective vaccines

  2024cites this paper
• Immunogenicity of mannan derived from Mycobacterium bovis as a promising adjuvant in vaccine BCG

  2024cites this paper
• The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer

  2024cites this paper
• Re-inventing traditional aluminum-based adjuvants: Insight into a century of advancements

  2024cites this paper
• BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models

  2024cites this paper
• Modular Display of Plasmodium yoelii Circumsporozoite Surface Protein and Merozoite Surface Protein-1 on Norovirus-like Particles.

  2024cites this paper
• Human in vitro modeling identifies adjuvant combinations that unlock antigen cross-presentation and promote T-helper 1 development in newborns, adults and elders.

  2024cites this paper
• Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer: An in-silico Study

  2024cites this paper
• The Use of an Adjuvant System Improves Innate and Adaptive Immune Response When Associated with a Leishmania (Viannia) braziliensis Antigen in a Vaccine Candidate against L. (Leishmania) infantum Infection

  2023cites this paper
• A DNA Prime and MVA Boost Strategy Provides a Robust Immunity against Infectious Bronchitis Virus in Chickens

  2023cites this paper
• Meeting vaccine formulation challenges in an emergency setting: towards the development of accessible vaccines.

  2023cites this paper
• Review: Current trends, challenges, and success stories in adjuvant research

  2023cites this paper
• Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress

  2023cites this paper
• New-age vaccine adjuvants, their development, and future perspective

  2023influential citation